Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Isambert, Nicolas ^a,b,c,d   Fumoleau, Pierre ^b,c   Paul, Catherine ^a,c,d   Ferrand, Christophe ^a   Zanetta, Sylvie ^b   Bauer, Jacques ^e   Ragot, Kevin ^c   Lizard, Gérard ^c   Jeannin, Jean François ^a,c,d   Bardou, Marc ^a,c  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

^d PSL RESEARCH UNIVERSITY   (France)

^e Vifor (International) Inc   (Switzerland)

Author keywords

Immune response; Lipid A analogue; OM 174; Phase I; Refractory solid tumors

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPID A DERIVATIVE; OM 174; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BREAST CANCER; BRONCHOSPASM; CANCER CONTROL; CHEMOTHERAPY INDUCED EMESIS; CHILL; CHOLESTASIS; CLINICAL ARTICLE; COLON CANCER; COLORECTAL CANCER; CYTOLYSIS; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSPHAGIA; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HEAD AND NECK CANCER; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; IMMUNE RESPONSE; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NATURAL KILLER CELL; NAUSEA; OPEN STUDY; OVARY CANCER; PHASE 1 CLINICAL TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KILLER CELLS, NATURAL; LIPOPOLYSACCHARIDES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; POLYMORPHISM, GENETIC; RATS; TOLL-LIKE RECEPTOR 4; TREATMENT OUTCOME;

EID: 84875486261     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-172     Document Type: Article

References (37)

1. Becker N, Altenburg HP, Stegmaier C, Ziegler H. Report on trends of incidence (1970-2002) of and mortality (1952-2002) from cancer in Germany. J Cancer Res Clin Oncol 2007, 133:23-35.
2. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009, 18:1688-1694. 10.1158/1055-9965.EPI-09-0090, 19505900.
3. Cress RD, Morris C, Ellison GL, Goodman MT. Secular changes in colorectal cancer incidence by subsite, stage at diagnosis, and race/ethnicity, 1992-2001. Cancer 2006, 107:1142-1152. 10.1002/cncr.22011, 16835912.
4. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I. Seeff LC, van BM, Goede SL, Ries LA: Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010, 116:544-573. 10.1002/cncr.24760, 3619726, 19998273.
5. Karim-Kos HE, De VE, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008, 44:1345-1389. 10.1016/j.ejca.2007.12.015, 18280139.
6. Heron M. Deaths: leading causes for 2007. Natl Vital Stat Rep 2011, 59:1-95.
7. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
8. Evans C, Dalgleish AG, Kumar D. Review article: immune suppression and colorectal cancer. Aliment Pharmacol Ther 2006, 24:1163-1177. 10.1111/j.1365-2036.2006.03075.x, 17014575.
9. Kemp TJ, Ludwig AT, Earel JK, Moore JM, Vanoosten RL, Moses B, Leidal K, Nauseef WM, Griffith TS. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood 2005, 106:3474-3482. 10.1182/blood-2005-03-1327, 1895062, 16037389.
10. Manegold C, Gravenor D, Woytowitz D, Mezger J, Hirsh V, Albert G, Al-Adhami M, Readett D, Krieg AM, Leichman CG. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3979-3986. 10.1200/JCO.2007.12.5807, 18711188.
11. Mauri D, Kamposioras K, Tsali L, Bristianou M, Valachis A, Karathanasi I, Georgiou C, Polyzos NP. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis. Cancer Treat Rev 2010, 36:69-74. 10.1016/j.ctrv.2009.10.006, 19945225.
12. Keogh B, Parker AE. Toll-like receptors as targets for immune disorders. Trends Pharmacol Sci 2011, 32:435-442. 10.1016/j.tips.2011.03.008, 21529972.
13. Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol 2009, 667:111-123. 10.1007/978-1-4419-1603-7_10, 20429221.
14. Palsson-McDermott EM, O'Neill LA. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 2004, 113:153-162. 10.1111/j.1365-2567.2004.01976.x, 1782563, 15379975.
15. Inagawa H, Nishizawa T, Noguchi K, Minamimura M, Takagi K, Goto S, Soma G, Mizuno D. Anti-tumor effect of lipopolysaccharide by intradermal administration as a novel drug delivery system. Anticancer Res 1997, 17:2153-2158.
16. Jeannin JF, Onier N. Lagadec P, von JN, Stutz P, Liehl E: Antitumor effect of synthetic derivatives of lipid A in an experimental model of colon cancer in the rat. Gastroenterology 1991, 101:726-733.
17. Onier N, Hilpert S, Arnould L, Saint-Giorgio V, Davies JG, Jeannin JF, Jeannin JF. Cure of colon cancer metastasis in rats with the new lipid A OM 174. Apoptosis of tumor cells and immunization of rats. Clin Exp Metastasis 1999, 17:299-306. 10.1023/A:1006663017149, 10545016.
18. Parr I, Wheeler E, Alexander P. Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA. Br J Cancer 1973, 27:370-389. 10.1038/bjc.1973.45, 2008799, 4713170.
19. Sassi N, Paul C, Martin A, Bettaieb A, Jeannin JF. Lipid A induced response in vivo. Lipid A in cancer therapy 2010, 69-80. Jeannin J, Springer edition.
20. Blondiau C, Lagadec P, Lejeune P, Onier N, Cavaillon JM, Jeannin JF. Correlation between the capacity to activate macrophages in vitro and the antitumor activity in vivo of lipopolysaccharides from different bacterial species. Immunobiology 1994, 190:243-254. 10.1016/S0171-2985(11)80272-X, 8088853.
21. van de Wiel PA, van der PA, Bloksma N. Role of tumour necrosis factor in the tumour-necrotizing activity of agents with diverging toxicity. Cancer Immunol Immunother 1991, 33:115-120. 10.1007/BF01742539, 2036659.
22. Reisser D, Pance A, Jeannin JF. Mechanisms of the antitumoral effect of lipid A. Bioessays 2002, 24:284-289. 10.1002/bies.10053, 11891766.
23. Onier N, Lejeune P, Martin M, Hammann A, Bauer J, Hirt P, Lagadec P, Jeannin JF. Involvement of T lymphocytes in curative effect of a new immunomodulator OM 163 on rat colon cancer metastases. Eur J Cancer 1993, 29A:2003-2009.
24. Shimizu T, Iida K, Iwamoto Y, Yanagihara Y, Ryoyama K, Asahara T, Ikeda K, Achiwa K. Biological activities and antitumor effects of synthetic lipid A analog linked N-acylated serine. Int J Immunopharmacol 1995, 17:425-431. 10.1016/0192-0561(95)00014-S, 7591367.
25. D'Agostini C, Pica F, Febbraro G, Grelli S, Chiavaroli C, Garaci E. Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions. Int Immunopharmacol 2005, 5:1205-1212. 10.1016/j.intimp.2005.02.013, 15914325.
26. Kiani A, Tschiersch A, Gaboriau E, Otto F, Seiz A, Knopf HP, Stutz P, Farber L, Haus U, Galanos C, Mertelsmann R, Engelhardt R. Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients. Blood 1997, 90:1673-1683.
27. de Bono JS, Dalgleish AG, Carmichael J, Diffley J, Lofts FJ, Fyffe D, Ellard S, Gordon RJ, Brindley CJ, Evans TR. Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin Cancer Res 2000, 6:397-405.
28. Vosika GJ, Barr C, Gilbertson D. Phase-I study of intravenous modified lipid A. Cancer Immunol Immunother 1984, 18:107-112.
29. Rickham PP. Human experimentation. Code of ethics of the World Medical Association. Declaration of Helsinki. Br Med J 1964, 2:177. 1816102, 14150898.
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
31. Lirussi F, Rakotoniaina Z, Madani S, Goirand F, Breuiller-Fouche M, Leroy MJ, Sagot P, Morrison JJ, Dumas M, Bardou M. ADRB3 adrenergic receptor is a key regulator of human myometrial apoptosis and inflammation during chorioamnionitis. Biol Reprod 2008, 78:497-505. 10.1095/biolreprod.107.064444, 17989355.
32. Prunet C, Montange T, Vejux A, Laubriet A, Rohmer JF, Riedinger JM, Athias A, Lemaire-Ewing S, Neel D, Petit JM, Steinmetz E, Brenot R, Gambert P, Lizard G. Multiplexed flow cytometric analyses of pro- and anti-inflammatory cytokines in the culture media of oxysterol-treated human monocytic cells and in the sera of atherosclerotic patients. Cytometry A 2006, 69:359-373.
33. Ducloux D, Deschamps M, Yannaraki M, Ferrand C, Bamoulid J, Saas P, Kazory A, Chalopin JM, Tiberghien P. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int 2005, 67:2454-2461. 10.1111/j.1523-1755.2005.00354.x, 15882292.
34. Ellegaard M, Bastholt L, Jakobsen A, Donskov F, Schmidt H. Interleukin-2-induced fever in relation to objective tumor response and survival in patients with metastatic melanoma. J Clin Oncol 2010, 28:15s.
35. Engelhardt R, Mackensen A, Galanos C. Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res 1991, 51:2524-2530.
36. Rockwell C, Morison D, Qureshi N. Lipid-A mediated tolerance and cancer therapy. Lipid A in cancer therapy 2010, 81-99. Jeannin J.
37. Garay RP, Viens P, Bauer J, Normier G, Bardou M, Jeannin JF, Chiavaroli C. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur J Pharmacol 2007, 563:1-17. 10.1016/j.ejphar.2007.02.018, 17383632.